rss
J Med Ethics 2000;26:47-50 doi:10.1136/jme.26.1.47

Narrowing the gap: access to HIV treatments in developing countries. A pharmaceutical company's perspective

  1. James Cochrane
  1. Glaxo Wellcome plc, Greenford, UK

      Abstract

      The advent of new antiretroviral medicines means that the effects of HIV can now be curbed, but only one in twenty infected people have so far benefited. For those living in developing countries, the new treatments are practically unattainable. Governments, UNAIDS and pharmaceutical companies recognise this only too well and have rethought established assumption in order to try and overcome the challenges posed by cost, inadequate health services and unreliable local supply of medicines.

      Footnotes

      • James Cochrane is Executive Director, Europe, the Middle East and Africa, Glaxo Wellcome plc, Greenford, Middlesex.

      This Article

      1. Abstract
      2. Full text
      3. PDF

      Responses

      1. Submit a response
      2. No responses published

      Register for free content

      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.